When attorneys first started calling about GLP-1 medications, the question was usually the same: how do you vet a gastroparesis claim? That question has not gone away. But in the past year, the population taking these drugs has changed, and the records you will be reading are changing with it.
The GLP-1 patient of 2026 is older, often frail, often on many other medications, and increasingly starting the drug through a telehealth visit or a pill rather than an injection their doctor taught them to use. That shift changes which cases appear, how they get framed, and what the record needs to show.
What changed in the past year
Three developments brought the new patient into view. In December 2025, the FDA approved the first GLP-1 pill for weight management, a daily oral form of Wegovy, and it launched in January. In April 2026, the FDA approved Lilly's oral GLP-1, orforglipron. And on July 1, 2026, Medicare began covering certain GLP-1s for weight management through a temporary demonstration program, with a copay of about $50 a month for many beneficiaries. For most of Medicare's history, federal law kept it from covering drugs for weight loss at all.
The drugs are easier to start, easier to afford for older adults, and easier to start without an established clinician relationship. A pill ordered after a short video visit leaves a very different record than an injection taught in person.
Where the litigation stands
The federal gastrointestinal cases remain consolidated in MDL 3094 in the Eastern District of Pennsylvania before Judge Karen S. Marston. As of early October 2026, 4,025 cases were pending. The court held its Rule 702 expert hearing in September. There has been no trial and no settlement program. The August 2025 ruling requiring a gastric emptying study to support a gastroparesis diagnosis still shapes which claims can proceed.
The vision loss cases in MDL 3163 are the fastest-growing part of the docket, rising from fewer than 100 cases in the spring to about 247 by October. A schedule entered in August places the major expert motions in mid-2027.
On the labels, the picture is mixed. The United Kingdom added a warning about NAION, a sudden loss of blood flow to the optic nerve, in February 2026, and Australia added NAION warnings in July. Europe's regulators reached a similar conclusion in 2025. As of this fall, the U.S. labels still do not include a specific NAION warning. In January 2026, the FDA moved in the other direction on a different risk, announcing it would remove suicidal-ideation language from GLP-1 labels after concluding the evidence did not support a causal link.
The risk that will grow fastest: muscle loss and falls
Rapid weight loss does not come only from fat. A meaningful share can be lean muscle. In a 45-year-old, that may matter little. In an 80-year-old who already walks with a cane, it can mean weakness, falls, and fractures.
That changes the cases you will see. Expect fewer claims that look like the classic gastroparesis case and more that look like ordinary elder injury cases, a fall, a hip fracture, dehydration, kidney injury, where a GLP-1 sits quietly in the medication list. Those cases may never be framed as drug cases at all. They may be malpractice claims against a prescriber, negligence claims against a nursing home, or claims against a telehealth company. The drug is part of the clinical story either way.
Consider an illustrative scenario. A 78-year-old woman with diabetes and arthritis sees an online ad and starts a GLP-1 through a telehealth service. Her video visit lasts eight minutes. Within six weeks she is on a higher dose. Over three months she loses 22 pounds. She is nauseated, eating little, and her daughter notices she is unsteady. She falls getting out of the tub and fractures her hip. At the hospital she is dehydrated, with acute kidney injury. Her primary care physician did not know she was on the drug.
The next wave of GLP-1 cases will often look like familiar elder injury cases, and the drug will be easy to miss if nobody reads the medication list with it in mind.
What the record should answer
Five questions frame the review, and they track the pillars of The Lexcura Clinical Intelligence Model: Record Integrity, Baseline, Imaging Analysis, Timeline Reconstruction, Standard of Care, Regulatory and Compliance Overlay, and Causation Mapping.
Where did the drug come from? Brand or compounded? Which pharmacy? The FDA has moved to restrict compounding now that shortages have ended, but many patients were on compounded products, and some still are. If the product was compounded, the analysis shifts away from the manufacturers and toward the pharmacy, the telehealth platform, and the prescriber. Record Integrity starts with knowing what was actually dispensed.
Was she an appropriate candidate, and was she screened? What did the intake ask? Was kidney function checked? Were her other medications reviewed? Did anyone consider her age, her fall risk, or her nutritional status? Baseline establishes what the patient brought to the drug before the first dose.
How fast was the dose increased? The labels call for gradual titration. Faster escalation raises the risk of severe GI effects, dehydration, and kidney injury. Timeline Reconstruction lays the dose changes against the weight loss, the symptoms, and the fall.
Who was watching? Did she report symptoms, and to whom? Was anyone tracking her weight, strength, or fluid intake? Was her primary care physician informed? Monitoring is a Standard of Care question, and the answer is usually found in what was charted, and what was not.
What else explains the fall? Arthritis, diabetes, other medications, vision, and home hazards all belong in the analysis. A fair causation opinion weighs each one. Causation Mapping tests whether the drug changed the outcome or whether the fall has a fuller explanation.
A note for long-term care
Facilities should know which residents are on GLP-1s, including residents admitted already taking one. A resident who stops eating or starts vomiting needs prompt attention. Weight loss that looks like treatment success in one setting can be malnutrition in another, and the federal nutrition and hydration standards still apply. Watch for residents who stopped the drug and restarted, sometimes at their old dose without re-titrating, because that can bring back severe GI effects.
The records that matter
- Telehealth intake forms, visit records, and the prescriber's credentials and state of licensure
- Pharmacy dispensing records showing the exact product, the dispensing pharmacy, and every dose change
- Documentation of the risks discussed
- Primary care records before and during use, including whether the PCP knew about the prescription
- Weights over time, kidney function, and electrolytes
- Records of reported symptoms and the response
- For facility residents: MDS assessments, dietary notes, intake records, and care plans
- For GI claims: the gastric emptying study, its protocol, and its timing relative to the drug
- For vision claims: the ophthalmology exam documenting NAION and records on other risk factors
Frequently Asked Questions
Is a GLP-1 case always a drug case?
No. Many of the cases now appearing are framed as malpractice claims against a prescriber, negligence claims against a nursing home, or claims against a telehealth company. The drug is part of the clinical story either way, and the record review is what shows how large a part it played.
What is NAION, and why does it matter in GLP-1 litigation?
NAION is a sudden loss of blood flow to the optic nerve. The United Kingdom, Australia, and European regulators have added warnings about it, while U.S. labels did not include a specific NAION warning as of fall 2026. Vision loss cases consolidated in MDL 3163 are the fastest-growing part of the GLP-1 docket.
Why does it matter whether the GLP-1 was compounded?
If the product was compounded, the analysis shifts away from the manufacturers and toward the pharmacy, the telehealth platform, and the prescriber. The FDA has moved to restrict compounding now that shortages have ended, but many patients were on compounded products, and some still are.
What records matter most when a GLP-1 patient falls?
Pharmacy dispensing records showing the exact product and every dose change, weights over time, kidney function and electrolytes, records of reported symptoms and the response, and primary care records showing whether the PCP knew about the prescription. For facility residents, add MDS assessments, dietary notes, intake records, and care plans.
About the Author
Michelle Carroll is the Founder and Chief Clinical Strategist of Lexcura Summit, where she leads clinical intelligence reviews of medical records for attorneys and healthcare organizations.
Talk to Us
If you are evaluating a case where a GLP-1 sits in the medication list, whether it is framed as a drug case or not, we would welcome the conversation. Visit lexcurasummit.com or book a brief conversation at calendly.com/michelle-lexcurasummit.